Compare RCG & CASI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RCG | CASI |
|---|---|---|
| Founded | N/A | 1991 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.1M | 19.7M |
| IPO Year | 1996 | 2023 |
| Metric | RCG | CASI |
|---|---|---|
| Price | $2.85 | $0.76 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 13.5K | ★ 16.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.11 | $0.74 |
| 52 Week High | $2.88 | $3.08 |
| Indicator | RCG | CASI |
|---|---|---|
| Relative Strength Index (RSI) | 63.18 | 36.83 |
| Support Level | $2.50 | N/A |
| Resistance Level | N/A | $1.07 |
| Average True Range (ATR) | 0.10 | 0.09 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 96.74 | 7.34 |
RENN Fund Inc is active in the financial services domain. It is a a registered, non-diversified, closed-end management investment company formed to provide return through capital appreciation and income by a long-term, value-oriented investment process that invests in a wide variety of financial instruments, including but not limited to, common stocks, fixed-income securities including convertible and non-convertible debt securities or loans, distressed debt, warrants, and preferred stock, exchange-traded funds and exchange-traded notes, and other instruments. It invests in various industries, including communication services, surgical and medical instruments and apparatus, oil and gas, medical chemicals, botanical products, etc.
CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA.